Literature DB >> 7699625

Decreasing costs and improving outcomes in systemic lupus erythematosus: using regression trees to develop health policy.

A E Clarke1, D A Bloch, D S Danoff, J M Esdaile.   

Abstract

OBJECTIVE: To characterize patients with systemic lupus erythematosus (SLE) who are expected to experience the highest direct and indirect monetary costs and greatest diminished productivity so that we may intervene to reduce costs and improve outcomes.
METHODS: We assessed demographics and health status in January, 1990 and costs incurred in the last 6 months of 1990 in January, 1991 in 151 patients with SLE enrolled in the Montreal General Hospital Lupus Registry. We used regression trees to separate low from high cost patients.
RESULTS: Patients with poor physical or poor psychological functioning incur the highest direct costs (3-fold and 1.6-fold the group mean, respectively); those with the poorest psychological functioning incur the highest indirect costs (2-fold the group average); and those with the most intense pain experience the greatest impairment in productivity (3-fold the group average).
CONCLUSION: Targeting patients with poor physical and psychological functioning and substantial pain with appropriate interventions may improve their outcomes and reduce disease costs. Targeting patients expected to have low costs with preventative interventions may delay worse outcomes and reduce future costs.

Entities:  

Mesh:

Year:  1994        PMID: 7699625

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

1.  A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets.

Authors:  S Jacobsen; J Petersen; S Ullman; P Junker; A Voss; J M Rasmussen; U Tarp; L H Poulsen; G van Overeem Hansen; B Skaarup; T M Hansen; J Pødenphant; P Halberg
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 2.  The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Authors:  Rachel Meacock; Nicola Dale; Mark J Harrison
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

3.  Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus.

Authors:  So-Yeon Park; Young Bin Joo; Jeeseon Shim; Yoon-Kyoung Sung; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2015-08-09       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.